Business Description
Jenburkt Pharmaceuticals Ltd
SIC : 2834
ISIN : INE354A01013
Share Class Description:
BOM:524731: Shs DematerialisedTotal Employee Number:
779Compare
Compare
Traded in other countries / regions
524731.India IPO Date
2000-11-27Description
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, production, development, and marketing of a wide range of branded pharmaceuticals and healthcare products. The Company operates in a single segment, Pharmaceutical Formulations. The Company generates key revenue from the local market.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.02 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.05 | |||||
Interest Coverage | 78.34 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 12.14 | |||||
Beneish M-Score | -2.19 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.6 | |||||
3-Year EBITDA Growth Rate | 13.5 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | -3.9 | |||||
3-Year Book Growth Rate | 17.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.86 | |||||
9-Day RSI | 31.04 | |||||
14-Day RSI | 34.55 | |||||
3-1 Month Momentum % | -10.91 | |||||
6-1 Month Momentum % | 3.48 | |||||
12-1 Month Momentum % | -6.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.11 | |||||
Quick Ratio | 3.52 | |||||
Cash Ratio | 2.04 | |||||
Days Inventory | 123.78 | |||||
Days Sales Outstanding | 48.92 | |||||
Days Payable | 97.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.12 | |||||
Dividend Payout Ratio | 0.22 | |||||
3-Year Dividend Growth Rate | 14.5 | |||||
Forward Dividend Yield % | 2.12 | |||||
5-Year Yield-on-Cost % | 2.12 | |||||
Shareholder Yield % | 2.26 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.96 | |||||
Operating Margin % | 22.39 | |||||
Net Margin % | 19.46 | |||||
EBITDA Margin % | 27.63 | |||||
FCF Margin % | 9.65 | |||||
OCF Margin % | 17.78 | |||||
ROE % | 17.85 | |||||
ROA % | 15.6 | |||||
ROIC % | 16.87 | |||||
3-Year ROIIC % | 11.18 | |||||
ROC (Joel Greenblatt) % | 54.97 | |||||
ROCE % | 23.01 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.15 | |||||
Forward PE Ratio | 10.84 | |||||
PE Ratio without NRI | 12.01 | |||||
Shiller PE Ratio | 16.6 | |||||
Price-to-Owner-Earnings | 10.66 | |||||
PEG Ratio | 0.75 | |||||
PS Ratio | 2.55 | |||||
PB Ratio | 2.19 | |||||
Price-to-Tangible-Book | 2.19 | |||||
Price-to-Free-Cash-Flow | 33.7 | |||||
Price-to-Operating-Cash-Flow | 16.27 | |||||
EV-to-EBIT | 8.88 | |||||
EV-to-EBITDA | 8.3 | |||||
EV-to-Revenue | 2.29 | |||||
EV-to-FCF | 31.2 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 1.41 | |||||
Price-to-DCF (Earnings Based) | 0.8 | |||||
Price-to-DCF (FCF Based) | 3.39 | |||||
Price-to-Median-PS-Value | 1.13 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.94 | |||||
Price-to-Graham-Number | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 6.53 | |||||
| Price-to-Net-Cash | 23.53 | |||||
Earnings Yield (Greenblatt) % | 11.27 | |||||
FCF Yield % | 2.97 | |||||
Forward Rate of Return (Yacktman) % | 18.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jenburkt Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,687.258 | ||
| EPS (TTM) (₹) | 74.388 | ||
| Beta | 1.0135 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 26.3 | ||
| 14-Day RSI | 34.55 | ||
| 14-Day ATR (₹) | 33.951697 | ||
| 20-Day SMA (₹) | 1029.0725 | ||
| 12-1 Month Momentum % | -6.44 | ||
| 52-Week Range (₹) | 944 - 1321 | ||
| Shares Outstanding (Mil) | 4.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jenburkt Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jenburkt Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 20.700000 Cash Dividend | 2026-08-28 | 1,030.55 (-3.67%) | ||
| INR 18.000000 Cash Dividend | 2025-07-11 | 1,385.70 (-1.02%) |
Show
Entries
Jenburkt Pharmaceuticals Ltd Frequently Asked Questions
What is Jenburkt Pharmaceuticals Ltd(BOM:524731)'s stock price today?
The current price of BOM:524731 is ₹978.00. The 52 week high of BOM:524731 is ₹1321.00 and 52 week low is ₹944.00.
When is next earnings date of Jenburkt Pharmaceuticals Ltd(BOM:524731)?
The next earnings date of Jenburkt Pharmaceuticals Ltd(BOM:524731) is .
Does Jenburkt Pharmaceuticals Ltd(BOM:524731) pay dividends? If so, how much?
The Dividend Yield %  of Jenburkt Pharmaceuticals Ltd(BOM:524731) is 2.12% (As of Today), Highest Dividend Payout Ratio of Jenburkt Pharmaceuticals Ltd(BOM:524731) was 0.57. The lowest was 0.03. And the median was 0.22. The  Forward Dividend Yield % of Jenburkt Pharmaceuticals Ltd(BOM:524731) is 2.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers